VSTM ▲ +0.1% - Verastem, Inc.
$VSTM Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
02-OCT-2026 07:30 AM ET
Share this post
More filings for $VSTM
VSTM ▼ -1.0% - Verastem, Inc.Sep 24, 2026VSTM ▲ +0.6% - Verastem, Inc.Sep 8, 2026VSTM - Verastem, Inc. - SEC Filing Update (14-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 14, 2026VSTM - Verastem, Inc. - SEC Filing Update (07-AUG-2026) | ThinkSabio - Stocks SimplifiedAug 7, 2026$VSTM SEC Filing Update (31-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 31, 2026$VSTM SEC Filing Update (30-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 30, 2026
View full $VSTM filing history →💬 Comments
Loading comments…
Leave a comment